Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NEU3 | Q9UQ49 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA3 | P07451 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfurous Acid SCHEMBL27394983 | 0.89 | HTT (0.50) | HTTCDC25BPKMTDP1KMT2A | |
| SCHEMBL3248878 | 0.85 | HTT (0.44) | HTTKMT2ASMN1; SMN2LMNAMAPK1 | |
| SCHEMBL11597521 | 0.84 | MAPT (0.43) | HTTPKMSMN1; SMN2ALDH1A1CA12 | |
| SCHEMBL31670536 | 0.83 | HTT (0.61) | HTTCDC25BPKMTDP1KMT2A | |
| SCHEMBL8100351 | 0.83 | HTT (0.61) | HTTCDC25BPKMTDP1KMT2A | |
| SCHEMBL8246019 | 0.81 | HTT (0.59) | HTTCDC25BPKMKMT2ASMN1; SMN2 | |
| SCHEMBL11344181 | 0.80 | KMT2A (0.44) | HTTPKMKMT2ASMN1; SMN2TSHR | |
| SCHEMBL9084678 | 0.80 | ALDH1A1 (0.49) | HTTPKMTDP1KMT2ASMN1; SMN2 | |
| SCHEMBL396004 | 0.79 | TDP1 (0.61) | HTTCDC25BTDP1KMT2ASMN1; SMN2 | |
| SCHEMBL7922220 | 0.79 | CDC25B (0.50) | HTTCDC25BPKMTDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-12377084-B2 | ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2025-08-05 | — | — | US | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | Grey Wolf Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | Grey Wolf Therapeutics Limited (GB) | 2024-07-02 | — | — | US | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-0659748-B1 | Substituted 1,1,-dioxo-2H-1,2-benzothiazinoylguanidines with Na+/H+-exchange inhibiting activity | HOECHST AG (DE) | 2000-07-12 | — | — | EP | disclosed |
| CN-1042933-C | Benzoylguanidine, preparation of same and application as pharmaceutical and pharmaceutical containing same | HOECHST AG (DE) | 1999-04-14 | — | — | CN | disclosed |
| US-5693672-A | 3,4,5-substituted benzoylguanidines, process for their preparation, their use as a medicament or diagnostic and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-02 | — | — | US | disclosed |
| US-5591754-A | Benzoylguanidines, pharmaceutical composition containing them and treatment of arrthythmias therewith | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-01-07 | — | — | US | disclosed |
| EP-0577024-B1 | 3,4,5 substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AG (DE) | 1996-10-16 | — | — | EP | disclosed |
| US-5547953-A | ANTIARRHYTHMIA AGENTS, ANTIISCHEMIC AGENTS, ANTIGROWTH AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-08-20 | — | — | US | disclosed |
| EP-0659748-A1 | Substituted 1-oxo-1,2-dihydro-isoquinolinoyl-and 1,1-dioxo-2H-1,2-benzothiazinoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-06-28 | — | — | EP | disclosed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | disclosed |
| EP-0577024-A1 | 3,4,5 substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366595-A1 | PHENYL-SULFAMOYL.BENZOYC ACIDS AS ERAP1 MODULATORS | CHP1, ERAP1, QSOX1 | HTT 1061/4885CDC25B 2018/4885PKM 4666/4885 |
| US-12377084-B2 | ERAP1 modulators | ERAP1, NR1I3, HRH4 | HTT 1206/4885CDC25B 2721/4885PKM 4349/4885 |
| US-12023333-B2 | Phenyl-sulfamoyl.benzoyc acids as ERAP1 modulators | ERAP1, CHP1, QSOX1 | HTT 993/4885CDC25B 2214/4885PKM 4631/4885 |
| US-20230416248-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | HTT 234/4885CDC25B 4258/4885PKM 2012/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | HTT 218/4885CDC25B 1746/4885PKM 1612/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | HTT 319/4885CDC25B 961/4885PKM 4363/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | HTT 319/4885CDC25B 961/4885PKM 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.